2023 ESMO WCGIC Insights: "Phase 3 LEAP-017 Study - Lenvatinib + Pembrolizumab vs. Standard of Care for Previously Treated mCRC" | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting

2023 ESMO WCGIC Insights: "Phase 3 LEAP-017 Study - Lenvatinib + Pembrolizumab vs. Standard of Care for Previously Treated mCRC"

By Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting FEATURING Akihito Kawazoe

By Insights from 2023 ESMO World Congress on Gastrointestinal Cancer Annual Meeting FEATURING Akihito Kawazoe

212 views

July 17, 2023

Comments 0

Login to view comments. Click here to Login